Advanced Search

Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2008 December;54(4) > Minerva Gastroenterologica e Dietologica 2008 December;54(4):359-64



A Journal on Gastroenterology, Nutrition and Dietetics

Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Quarterly

ISSN 1121-421X

Online ISSN 1827-1642


Minerva Gastroenterologica e Dietologica 2008 December;54(4):359-64


Autoimunne pancreatitis

Dite P., Trna J., Novotny I.

Department of Hepatogastroenterology University Hospital of Brno, Brno, Czech Republic

Since Sarles et al. in 1961 reported a particular type of pancreatitis with hypergammaglobulinemia, many investigators have suggested that an autoimmune mechanism may be involved in some patients with pancreatitis. Recently, the concept of autoimmune pancreatitis (AIP) has been proposed in which several unique clinical, biochemical and imaging signs have been shown. In the TIGARO risk factor classification system of chronic pancreatitis proposed in 2001, autoimmunity was categorized as one of six of the risk factors. AIP is a chronic fibroinflammatory condition primary affecting pancreas. It is an atypical form of chronic pancreatitis characterized by sonolucent swelling of the pancreas, diffuse irregular narrowing of the pancreatic duct, and high serum IgG4 concentrations. Co-occurrence of extrapancreatic involvement, such as sclerosing cholangitis, retroperitoneal fibrosis, or salivarygland swelling were found: Histopathologic examinations detected extrapancreatic lesions such as lymphoplasmacytic inflammation and fibrosis, similar to those present in the pancreatic tissue, suggesting a common pathogenesis. These findings suggest that the disease involves a general involvement of the digestive system, although the presence of such involvement has not been fully elucidated. Steroids are a main therapeutic option in AIP.

language: English


top of page